For research use only. Not for therapeutic Use.
Pomalidomide-C3-adavosertib（Cat No.:I038762）is a novel combination therapy designed to enhance the therapeutic effects of both pomalidomide and adavosertib. Pomalidomide is an immunomodulatory drug used primarily in the treatment of multiple myeloma, while adavosertib is an inhibitor of the ATR (Ataxia Telangiectasia and Rad3-Related) kinase, which plays a role in DNA damage response. The combination aims to potentiate antitumor effects by inhibiting DNA repair mechanisms in cancer cells, making them more susceptible to treatment. This combination is being investigated in clinical trials for its potential efficacy in treating hematological cancers and other malignancies.
| CAS Number | 2414418-49-6 |
| Synonyms | 2-(2,6-dioxopiperidin-3-yl)-4-[3-[4-[4-[[1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-3-oxo-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]piperazin-1-yl]propylamino]isoindole-1,3-dione |
| Molecular Formula | C42H45N11O6 |
| Purity | ≥95% |
| IUPAC Name | 2-(2,6-dioxopiperidin-3-yl)-4-[3-[4-[4-[[1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-3-oxo-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-6-yl]amino]phenyl]piperazin-1-yl]propylamino]isoindole-1,3-dione |
| InChI | InChI=1S/C42H45N11O6/c1-4-19-51-38(56)29-25-44-41(48-36(29)53(51)33-11-6-10-32(46-33)42(2,3)59)45-26-12-14-27(15-13-26)50-23-21-49(22-24-50)20-7-18-43-30-9-5-8-28-35(30)40(58)52(39(28)57)31-16-17-34(54)47-37(31)55/h4-6,8-15,25,31,43,59H,1,7,16-24H2,2-3H3,(H,44,45,48)(H,47,54,55) |
| InChIKey | LZUDSNUROXNVPH-UHFFFAOYSA-N |
| SMILES | CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)CCCNC6=CC=CC7=C6C(=O)N(C7=O)C8CCC(=O)NC8=O)O |
